Overcoming macrophage-mediated axonal dieback following CNS injury.
Trauma to the adult CNS initiates multiple processes including primary and secondary axotomy, inflammation, and glial scar formation that have devastating effects on neuronal regeneration. After spinal cord injury, the infiltration of phagocytic macrophages coincides with long-distance axonal retraction from the initial site of injury, a deleterious phenomenon known as axonal dieback. We have previously shown that activated macrophages directly induce long-distance retraction of dystrophic axons in an in vitro model of the glial scar. We hypothesized that treatments that are primarily thought to increase neuronal regeneration following spinal cord injury may in fact derive a portion of their beneficial effects from inhibition of macrophage-mediated axonal retraction. We analyzed the effects of protease inhibition, substrate modification, and neuronal preconditioning on macrophage-axon interactions using our established in vitro model. General inhibition of matrix metalloproteinases and specific inhibition of MMP-9 prevented macrophage-induced axonal retraction despite significant physical interactions between the two cell types, whereas inhibition of MMP-2 had no effect. Chondroitinase ABC-mediated digestion of the aggrecan substrate also prevented macrophage-induced axonal retraction in the presence of extensive macrophage-axon interactions. The use of a conditioning lesion to stimulate intrinsic neuronal growth potential in the absence of substrate modification likewise prevented macrophage-induced axonal retraction in vitro and in vivo following spinal cord injury. These data provide valuable insight into the cellular and molecular mechanisms underlying macrophage-mediated axonal retraction and demonstrate modifications that can alleviate the detrimental effects of this unfavorable phenomenon on the postlesion CNS.
Busch
Sarah A
SA
Department of Neurosciences, Case Western Reserve University, Cleveland, Ohio 44106, USA.
Horn
Kevin P
KP
Silver
Daniel J
DJ
Silver
Jerry
J
D053674:Aggrecans / Q000378:metabolism; D000818:Animals; D001369:Axons / Q000502:physiology*; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D019765:Chondroitin ABC Lyase / Q000378:metabolism; D005260:Female; D005727:Ganglia, Spinal / Q000196:embryology / Q000502:physiology; D020439:Growth Cones / Q000502:physiology; D008264:Macrophages / Q000502:physiology*; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D061965:Matrix Metalloproteinase Inhibitors; D009410:Nerve Degeneration / Q000209:etiology / Q000503:physiopathology*; D009457:Neuroglia / Q000502:physiology; D011509:Proteoglycans / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D013119:Spinal Cord Injuries / Q000150:complications / Q000503:physiopathology*; D014741:Video Recording
D053674:Aggrecans; D061965:Matrix Metalloproteinase Inhibitors; D011509:Proteoglycans; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9; D019765:Chondroitin ABC Lyase
J Neurosci. 2002 Sep 1;22(17):7526-35
12196576
J Neurosci. 2000 Jan 1;20(1):315-25
10627609
J Neurosci. 2004 Jul 21;24(29):6531-9
15269264
J Neurosci. 2002 Dec 1;22(23):10408-15
12451140
Nat Rev Neurosci. 2001 Jul;2(7):502-11
11433375
Neuron. 2002 Jun 13;34(6):885-93
12086637
Nat Rev Neurosci. 2006 Aug;7(8):617-27
16858390
J Neurosci. 2006 Oct 18;26(42):10856-67
17050723
J Neurosci. 2006 Jul 12;26(28):7405-15
16837588
Exp Neurol. 2008 Feb;209(2):483-96
17936753
Mol Cell Neurosci. 2001 Jun;17(6):945-56
11414785
Brain. 2005 Jul;128(Pt 7):1622-33
15800021
Exp Neurol. 2008 Apr;210(2):331-8
18158149
J Neurosci. 2007 Jul 25;27(30):7911-20
17652582
Nat Rev Neurosci. 2005 Dec;6(12):931-44
16288297
Curr Opin Neurobiol. 2007 Feb;17(1):120-7
17223033
J Neurosci. 2003 Dec 3;23(35):11127-35
14657171
Cell Calcium. 1993 Nov;14(10):736-45
8131190
J Neurosci. 2006 Sep 27;26(39):9841-50
17005848
J Neurotrauma. 2006 Mar-Apr;23(3-4):371-83
16629623
J Biol Chem. 2002 Dec 6;277(49):47461-8
12354772
J Neurosci. 2003 Mar 15;23(6):2284-93
12657687
Nat Rev Neurosci. 2003 Sep;4(9):703-13
12951563
Nat Rev Neurosci. 2008 Jun;9(6):481-93
18490917
J Neurosurg. 2003 Sep;99(2 Suppl):188-97
12956462
J Neurosci. 1999 Jul 15;19(14):5810-22
10407022
J Neurosci. 2001 Jan 1;21(1):92-7
11150324
J Neurosci. 2008 Sep 17;28(38):9330-41
18799667
J Neurosci. 2008 Apr 30;28(18):4613-8
18448637
Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16848-52
16275900
Mol Cell Neurosci. 2003 Mar;22(3):383-95
12691739
J Neurosci. 2007 Aug 22;27(34):9169-80
17715353
Nat Rev Neurosci. 2004 Feb;5(2):146-56
14735117
J Neurosci. 2005 Aug 31;25(35):8066-76
16135764
J Neurosci. 2006 Apr 19;26(16):4406-14
16624960
J Neurosci. 2001 Jul 1;21(13):4782-8
11425905
Nat Rev Immunol. 2004 Aug;4(8):617-29
15286728
Dev Neurobiol. 2007 Aug;67(9):1166-82
17514714
Neuron. 1999 May;23(1):83-91
10402195
Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8786-90
15173585
Neuron. 2002 Jul 3;35(1):13-6
12123603
Circ Res. 2004 Aug 20;95(4):364-71
15256478
Nat Rev Neurosci. 2003 Dec;4(12):981-90
14682360
Neuron. 2002 Jun 13;34(6):895-903
12086638
Nature. 1984 Jun 28-Jul 4;309(5971):791-3
6204205
J Immunol. 2008 Mar 1;180(5):2999-3006
18292522
J Neuroimmunol. 1997 Feb;72(2):155-61
9042108
Nature. 2002 Apr 11;416(6881):636-40
11948352